Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on developing advanced cancer treatments, has scheduled the release of its first quarter 2025 financial results for Monday, May 12, 2025, after market close. The company will also provide a business update at that time. The financial report and business highlights will be accessible through the newsroom section of Perspective's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda radiopharmaceutica specializzata nello sviluppo di trattamenti avanzati contro il cancro, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025, dopo la chiusura del mercato. In quell'occasione, l'azienda fornirà anche un aggiornamento sullo stato del business. Il rapporto finanziario e i principali aggiornamenti saranno disponibili nella sezione newsroom del sito web di Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía radiofarmacéutica enfocada en el desarrollo de tratamientos avanzados contra el cáncer, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, después del cierre del mercado. La empresa también ofrecerá una actualización sobre el negocio en ese momento. El informe financiero y los aspectos destacados estarán disponibles en la sección de noticias del sitio web de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 첨단 암 치료제 개발에 주력하는 방사성 의약품 회사로, 2025년 1분기 재무 결과를 2025년 5월 12일 월요일 장 마감 후에 발표할 예정입니다. 회사는 이와 함께 사업 현황 업데이트도 제공할 예정입니다. 재무 보고서와 주요 사업 내용은 Perspective 웹사이트의 뉴스룸 섹션에서 확인할 수 있습니다.
Perspective Therapeutics (NYSE AMERICAN : CATX), une entreprise radiopharmaceutique spécialisée dans le développement de traitements avancés contre le cancer, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025, après la clôture des marchés. La société fournira également une mise à jour commerciale à cette occasion. Le rapport financier et les points forts seront accessibles via la section newsroom du site web de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein auf die Entwicklung fortschrittlicher Krebstherapien spezialisiertes Radiopharmaunternehmen, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird zu diesem Zeitpunkt auch ein Geschäftsupdate geben. Der Finanzbericht und die wichtigsten Geschäftsinformationen werden im Newsroom-Bereich der Website von Perspective verfügbar sein.
- None.
- None.
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 12, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and therapy trials in the U.S. for the treatment of metastatic melanoma and neuroendocrine tumors, respectively. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) release Q1 2025 earnings?
Where can I find CATX's Q1 2025 financial results?
What type of company is Perspective Therapeutics (CATX)?
What stock exchange is CATX listed on?
